{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:18:45Z","timestamp":1780924725262,"version":"3.54.1"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["5P30CA056036-17"],"award-info":[{"award-number":["5P30CA056036-17"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["1R03CA283232-01"],"award-info":[{"award-number":["1R03CA283232-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001784","name":"Pancreatic Cancer Action Network","doi-asserted-by":"publisher","award":["21-20-JAIN"],"award-info":[{"award-number":["21-20-JAIN"]}],"id":[{"id":"10.13039\/100001784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002135","name":"Hirshberg Foundation for Pancreatic Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002135","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008237","name":"Department of Surgery","doi-asserted-by":"publisher","award":["UO1 CA224012"],"award-info":[{"award-number":["UO1 CA224012"]}],"id":[{"id":"10.13039\/100008237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008237","name":"Department of Surgery","doi-asserted-by":"publisher","award":["R21 CA263996"],"award-info":[{"award-number":["R21 CA263996"]}],"id":[{"id":"10.13039\/100008237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008237","name":"Department of Surgery","doi-asserted-by":"publisher","award":["RO1 CA212600"],"award-info":[{"award-number":["RO1 CA212600"]}],"id":[{"id":"10.13039\/100008237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019461","name":"Oregon Institute of Occupational Health Sciences, Oregon Health and Science University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.neo.2025.101152","type":"journal-article","created":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:37Z","timestamp":1742083237000},"page":"101152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma"],"prefix":"10.1016","volume":"63","author":[{"given":"Sohum","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2651-9575","authenticated-orcid":false,"given":"Eleanor","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutuj P","family":"Kusurkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5928-0559","authenticated-orcid":false,"given":"Avinoam","family":"Nevler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1165-9041","authenticated-orcid":false,"given":"Michael J","family":"Pishvaian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie C","family":"Sears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R","family":"Brody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8097-0071","authenticated-orcid":false,"given":"Charles J","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9383-7501","authenticated-orcid":false,"given":"Aditi","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neo.2025.101152_bib0001","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1067\/j.cpradiol.2007.08.004","article-title":"Uncommon tumors and pseudotumoral lesions of the pancreas","volume":"37","author":"de Juan","year":"2008","journal-title":"Curr. Probl. Diagn. Radiol."},{"issue":"9","key":"10.1016\/j.neo.2025.101152_bib0002","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic Cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMa"},{"issue":"1","key":"10.1016\/j.neo.2025.101152_bib0003","first-page":"8","article-title":"Cancer statistics 2024: all hands on deck","volume":"74","author":"Dizon","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.neo.2025.101152_bib0004","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/14737140.2019.1622417","article-title":"Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma","volume":"19","author":"Pandey","year":"2019","journal-title":"Expert. Rev. AntiCancer Ther."},{"issue":"39","key":"10.1016\/j.neo.2025.101152_bib0005","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.3748\/wjg.v27.i39.6527","article-title":"Therapeutic resistance in pancreatic ductal adenocarcinoma: current challenges and future opportunities","volume":"27","author":"Jain","year":"2021","journal-title":"World J. Gastroenterol."},{"issue":"25","key":"10.1016\/j.neo.2025.101152_bib0006","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.neo.2025.101152_bib0007","doi-asserted-by":"crossref","first-page":"463","DOI":"10.5732\/cjc.011.10111","article-title":"PARP inhibitors: its role in treatment of cancer","volume":"30","author":"Chen","year":"2011","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.neo.2025.101152_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.880643","article-title":"Homologous recombination deficiency in ovarian, breast, colorectal, pancreatic, non-small cell lung and prostate cancers, and the mechanisms of resistance to PARP inhibitors","volume":"12","author":"Mekonnen","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.neo.2025.101152_bib0009","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1002\/onco.13551","article-title":"FDA approval summary: olaparib monotherapy or in combination with Bevacizumab for the maintenance treatment of patients with advanced ovarian cancer","volume":"26","author":"Arora","year":"2021","journal-title":"Oncologist."},{"issue":"4","key":"10.1016\/j.neo.2025.101152_bib0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.neo.2025.101152_bib0011","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12943-020-01167-9","article-title":"PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications","volume":"19","author":"Zhu","year":"2020","journal-title":"Mol. Cancer"},{"issue":"19","key":"10.1016\/j.neo.2025.101152_bib0012","doi-asserted-by":"crossref","first-page":"5092","DOI":"10.1158\/1078-0432.CCR-20-1301","article-title":"A phase I\/II study of Veliparib (ABT-888) in combination with 5-fluorouracil and oxaliplatin in patients with metastatic pancreatic cancer","volume":"26","author":"Pishvaian","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2025.101152_bib0013","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.2147\/CMAR.S211151","article-title":"BRCA mutations in pancreas cancer: spectrum, current management, challenges and future prospects","volume":"12","author":"Wong","year":"2020","journal-title":"Cancer Manage Res."},{"issue":"12","key":"10.1016\/j.neo.2025.101152_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/genes8120375","article-title":"Dualistic role of BARD1 in cancer","volume":"8","author":"Cimmino","year":"2017","journal-title":"Genes. (Basel)"},{"issue":"7","key":"10.1016\/j.neo.2025.101152_bib0015","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nsmb.3236","article-title":"Human BRCA1-BARD1 ubiquitin ligase activity counteracts chromatin barriers to DNA resection","volume":"23","author":"Densham","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"7676","key":"10.1016\/j.neo.2025.101152_bib0016","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature24060","article-title":"BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing","volume":"550","author":"Zhao","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.neo.2025.101152_bib0017","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev-biochem-013118-111058","article-title":"The BRCA tumor suppressor network in chromosome damage repair by homologous recombination","volume":"88","author":"Zhao","year":"2019","journal-title":"Annu. Rev. Biochem."},{"issue":"5","key":"10.1016\/j.neo.2025.101152_bib0018","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41580-020-0218-z","article-title":"The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication","volume":"21","author":"Tarsounas","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.neo.2025.101152_bib0019","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S1357-2725(01)00161-3","article-title":"BRCA1-dependent and independent functions of BARD1","volume":"34","author":"Irminger-Finger","year":"2002","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"2","key":"10.1016\/j.neo.2025.101152_bib0020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2009.10.079","article-title":"BARD1, a possible biomarker for breast and ovarian cancer","volume":"117","author":"Irminger-Finger","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"24","key":"10.1016\/j.neo.2025.101152_bib0021","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1158\/0008-5472.CAN-07-2370","article-title":"Oncogenic BARD1 isoforms expressed in gynecological cancers","volume":"67","author":"Li","year":"2007","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.neo.2025.101152_bib0022","doi-asserted-by":"crossref","first-page":"7649","DOI":"10.1038\/s41598-017-07962-7","article-title":"Up-regulation of BRCA1-associated RING domain 1 promotes hepatocellular carcinoma progression by targeting Akt signaling","volume":"7","author":"Liao","year":"2017","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.neo.2025.101152_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182356","article-title":"BARD1 serum autoantibodies for the detection of lung cancer","volume":"12","author":"Pilyugin","year":"2017","journal-title":"PLoS. One"},{"issue":"2","key":"10.1016\/j.neo.2025.101152_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/genes12020320","article-title":"Differential expression of BARD1 isoforms in melanoma","volume":"12","author":"McDougall","year":"2021","journal-title":"Genes. (Basel)"},{"issue":"7","key":"10.1016\/j.neo.2025.101152_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/genes11070829","article-title":"The effects of genetic and epigenetic alterations of BARD1 on the development of non-breast and non-gynecological cancers","volume":"11","author":"Watters","year":"2020","journal-title":"Genes. (Basel)"},{"issue":"5","key":"10.1016\/j.neo.2025.101152_bib0026","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/ijc.21428","article-title":"Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis","volume":"118","author":"Wu","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.neo.2025.101152_bib0027","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.biocel.2009.12.025","article-title":"Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1","volume":"42","author":"Dizin","year":"2010","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"1","key":"10.1016\/j.neo.2025.101152_bib0028","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1186\/s12885-022-09567-4","article-title":"BARD1 mystery: tumor suppressors are cancer susceptibility genes","volume":"22","author":"Hawsawi","year":"2022","journal-title":"BMC. Cancer"},{"key":"10.1016\/j.neo.2025.101152_bib0029","doi-asserted-by":"crossref","first-page":"26273","DOI":"10.1038\/srep26273","article-title":"Expression of an oncogenic BARD1 splice variant impairs homologous recombination and predicts response to PARP-1 inhibitor therapy in colon cancer","volume":"6","author":"Ozden","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.neo.2025.101152_bib0030","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1038\/s41467-018-03951-0","article-title":"Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1","volume":"9","author":"Zhu","year":"2018","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.neo.2025.101152_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071848","article-title":"HuR plays a role in double-strand break repair in pancreatic cancer cells and regulates functional BRCA1-associated-ring-domain-1(BARD1) isoforms","volume":"14","author":"Jain","year":"2022","journal-title":"Cancers. (Basel)"},{"issue":"6","key":"10.1016\/j.neo.2025.101152_bib0032","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.7150\/jca.36164","article-title":"Functional characterization of full-length BARD1 strengthens its role as a tumor suppressor in neuroblastoma","volume":"11","author":"Cimmino","year":"2020","journal-title":"J. Cancer"},{"issue":"29","key":"10.1016\/j.neo.2025.101152_bib0033","doi-asserted-by":"crossref","first-page":"27312","DOI":"10.18632\/oncotarget.4743","article-title":"Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells","volume":"6","author":"Jimbo","year":"2015","journal-title":"Oncotarget."},{"issue":"10","key":"10.1016\/j.neo.2025.101152_bib0034","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/1541-7786.MCR-19-0589","article-title":"Abemaciclib is effective against pancreatic cancer cells and synergizes with HuR and YAP1 inhibition","volume":"17","author":"Dhir","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"17","key":"10.1016\/j.neo.2025.101152_bib0035","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/0008-5472.CAN-18-3645","article-title":"Poly (ADP) ribose glycohydrolase can Be effectively targeted in pancreatic cancer","volume":"79","author":"Jain","year":"2019","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.neo.2025.101152_bib0036","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.neo.2025.101152_bib0037","doi-asserted-by":"crossref","DOI":"10.1158\/1541-7786.MCR-20-0985","article-title":"AraC-FdUMP[10](CF10) is a next generation fluoropyrimidine with potent antitumor activity in PDAC and synergy with PARG inhibition","author":"Haber","year":"2021","journal-title":"Mol. Cancer Res."},{"issue":"5","key":"10.1016\/j.neo.2025.101152_bib0038","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1073\/pnas.050586197","article-title":"Identification of CDK4 as a target of c-MYC","volume":"97","author":"Hermeking","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.neo.2025.101152_bib0039","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s42003-019-0353-2","article-title":"Myc-driven chromatin accessibility regulates Cdc45 assembly into CMG helicases","volume":"2","author":"Nepon-Sixt","year":"2019","journal-title":"Commun. Biol."},{"issue":"4","key":"10.1016\/j.neo.2025.101152_bib0040","doi-asserted-by":"crossref","DOI":"10.1002\/bies.201900218","article-title":"Myc and the replicative CMG helicase: the creation and destruction of cancer: myc over-activation of CMG helicases drives tumorigenesis and creates a vulnerability in CMGs for therapeutic intervention","volume":"42","author":"Reed","year":"2020","journal-title":"Bioessays"},{"key":"10.1016\/j.neo.2025.101152_bib0041","article-title":"Validating RRP12 expression and its prognostic significance in HCC based on data mining and bioinformatics methods","volume":"12","author":"Wei","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.neo.2025.101152_bib0042","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/s41467-017-01967-6","article-title":"MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance","volume":"8","author":"Farrell","year":"2017","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.neo.2025.101152_bib0043","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.onc.1201520","article-title":"Regulation of c-myc expression by Ras\/Raf signalling","volume":"16","author":"Kerkhoff","year":"1998","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.neo.2025.101152_bib0044","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221524","article-title":"MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4\/6 and lysosomal inhibition","volume":"220","author":"Silvis","year":"2023","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.neo.2025.101152_bib0045","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1158\/1535-7163.MCT-16-0050","article-title":"Concepts to target MYC in pancreatic cancer","volume":"15","author":"Wirth","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.neo.2025.101152_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.851512","article-title":"c-Myc-PD-L1 Axis sustained gemcitabine-resistance in pancreatic cancer","volume":"13","author":"Yao","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.neo.2025.101152_bib0047","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1101\/gad.1920310","article-title":"Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells","volume":"24","author":"Choi","year":"2010","journal-title":"Genes Dev."},{"issue":"10","key":"10.1016\/j.neo.2025.101152_bib0048","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/onc.2012.144","article-title":"The ubiquitin ligase CHIP regulates c-myc stability and transcriptional activity","volume":"32","author":"Paul","year":"2013","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.neo.2025.101152_bib0049","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S1097-2765(03)00173-4","article-title":"Skp2 regulates Myc protein stability and activity","volume":"11","author":"Kim","year":"2003","journal-title":"Mol. Cell"},{"issue":"20","key":"10.1016\/j.neo.2025.101152_bib0050","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.cub.2004.09.083","article-title":"A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-myc and cell size","volume":"14","author":"Welcker","year":"2004","journal-title":"Curr. Biol."},{"issue":"24","key":"10.1016\/j.neo.2025.101152_bib0051","doi-asserted-by":"crossref","first-page":"9085","DOI":"10.1073\/pnas.0402770101","article-title":"The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation","volume":"101","author":"Welcker","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.neo.2025.101152_bib0052","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-3-031-30065-3_8","article-title":"Strategies for the management of patients with pancreatic cancer with PARP inhibitors","volume":"186","author":"Golan","year":"2023","journal-title":"Cancer Treat. Res."},{"issue":"20","key":"10.1016\/j.neo.2025.101152_bib0053","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1158\/0008-5472.CAN-15-3240","article-title":"The PARP inhibitor AZD2461 provides insights into the role of PARP3 inhibition for both synthetic lethality and tolerability with chemotherapy in preclinical models","volume":"76","author":"Oplustil O'Connor","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.neo.2025.101152_bib0054","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.neo.2025.101152_bib0055","doi-asserted-by":"crossref","first-page":"962","DOI":"10.2174\/1389450121666200203162541","article-title":"BRCA mutational status is a promising predictive biomarker for platinum- based chemotherapy in triple-negative breast cancer","volume":"21","author":"Tazzite","year":"2020","journal-title":"Curr. Drug Targets."},{"issue":"4","key":"10.1016\/j.neo.2025.101152_bib0056","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00018-019-03299-8","article-title":"Targeting DNA repair in cancer: current state and novel approaches","volume":"77","author":"Klinakis","year":"2020","journal-title":"Cell Mol. Life Sci."},{"issue":"10","key":"10.1016\/j.neo.2025.101152_bib0057","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/s41416-021-01469-9","article-title":"BRCA-mutant pancreatic ductal adenocarcinoma","volume":"125","author":"Lai","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.neo.2025.101152_bib0058","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.neo.2025.101152_bib0059","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1667\/RR13515.1","article-title":"DNA damage response genes and the development of cancer metastasis","volume":"181","author":"Broustas","year":"2014","journal-title":"Radiat. Res."},{"key":"10.1016\/j.neo.2025.101152_bib0060","doi-asserted-by":"crossref","unstructured":"Yin, M., F. Hong, and Q.E. Wang, DNA damage response and cancer metastasis: clinical implications and therapeutic opportunities, in metastasis, C.M. Sergi, editor. 2022: brisbane (AU).","DOI":"10.36255\/exon-publications.metastasis.dna-damage-response"},{"issue":"10","key":"10.1016\/j.neo.2025.101152_bib0061","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.18632\/oncotarget.1923","article-title":"Rad51 supports triple negative breast cancer metastasis","volume":"5","author":"Wiegmans","year":"2014","journal-title":"Oncotarget."},{"issue":"4","key":"10.1016\/j.neo.2025.101152_bib0062","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MPA.0b013e3181c15963","article-title":"Phenotype and genotype of pancreatic cancer cell lines","volume":"39","author":"Deer","year":"2010","journal-title":"Pancreas."},{"key":"10.1016\/j.neo.2025.101152_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2023.106372","article-title":"The c-myc targeting hnRNPAB promotes lung adenocarcinoma cell proliferation via stabilization of CDK4 mRNA","volume":"156","author":"Xu","year":"2023","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"13","key":"10.1016\/j.neo.2025.101152_bib0064","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/onc.2015.216","article-title":"MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies","volume":"35","author":"Hessmann","year":"2016","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.neo.2025.101152_bib0065","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12032-022-01834-5","article-title":"Glutamine stabilizes myc via alpha-ketoglutarate and regulates paclitaxel sensitivity","volume":"39","author":"Bhardwaj","year":"2022","journal-title":"Med. Oncol."},{"issue":"2","key":"10.1016\/j.neo.2025.101152_bib0066","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1158\/2159-8290.CD-20-1826","article-title":"MYC levels regulate metastatic heterogeneity in pancreatic adenocarcinoma","volume":"12","author":"Maddipati","year":"2022","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.neo.2025.101152_bib0067","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1158\/2159-8290.CD-19-0435","article-title":"MYC instructs and maintains pancreatic adenocarcinoma phenotype","volume":"10","author":"Sodir","year":"2020","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.neo.2025.101152_bib0068","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ncb1110","article-title":"A signalling pathway controlling c-myc degradation that impacts oncogenic transformation of human cells","volume":"6","author":"Yeh","year":"2004","journal-title":"Nat. Cell Biol."},{"issue":"19","key":"10.1016\/j.neo.2025.101152_bib0069","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.4161\/cc.6.19.4804","article-title":"Fbw7 and Usp28 regulate myc protein stability in response to DNA damage","volume":"6","author":"Popov","year":"2007","journal-title":"Cell Cycle"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625000314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625000314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:32:32Z","timestamp":1762547552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558625000314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":69,"alternative-id":["S1476558625000314"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2025.101152","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2025.101152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101152"}}